Sanofi CEO reiterates R&D bet is best long-term approach, addresses probe on market manipulation allegations
Although Sanofi CEO Paul Hudson was at the Financial Times’ Global Pharma and Biotech Summit to talk about AI, there was no avoiding the questions about its recent move to spin out its consumer unit as well as the investigation in France over alleged misleading financial communications.
Hudson reiterated that the consumer unit spinout was all about Sanofi investing in the science. But this was at the cost of abandoning its earnings guidance for 2025.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.